Key highlights
21 August 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
16 August 2023 – 1 mins read
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in…
27 July 2023 – 1 mins read
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…
19 July 2023 – 1 mins read
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
PARIS, FRANCE, 19 July 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 158 Press Releases
No results available. Try modifying the filter criteria.
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links
